Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.39 |
| ▸ | ATR | Q13535 | 4/20 | 0.38 |
| ▸ | PRKDC | P78527 | 2/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrole SCHEMBL11786833 | 0.88 | GRM5 (0.47) | GRM5MEN1KMT2ASIRT6TDP1 | |
| SCHEMBL3632923 | 0.84 | MEN1 (0.43) | GRM5MEN1KMT2ASIRT6TDP1 | |
| SCHEMBL30504276 | 0.83 | GRM5 (0.55) | GRM5ALDH1A1MAPKAPK2ATRPRKDC | |
| SCHEMBL11786153 | 0.83 | GRM5 (0.55) | GRM5ALDH1A1MAPKAPK2ATRPRKDC | |
| SCHEMBL30504253 | 0.82 | GRM5 (0.51) | GRM5MEN1KMT2ASIRT6MAPKAPK2 | |
| SCHEMBL20046666 | 0.81 | MEN1 (0.47) | GRM5MEN1KMT2ASIRT6TDP1 | |
| SCHEMBL29844710 | 0.79 | GRM5 (0.52) | GRM5ALDH1A1MAPKAPK2PIM1PIM3 | |
| SCHEMBL261816 | 0.79 | GRM5 (0.52) | GRM5ALDH1A1MAPKAPK2PIM1PIM3 | |
| SCHEMBL10256130 | 0.79 | PLAU (0.46) | KMT2ATDP1ALDH1A1ATRPRKDC | |
| SCHEMBL6377192 | 0.79 | MEN1 (0.46) | GRM5MEN1KMT2ASIRT6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| CN-119977893-A | Preparation method and application of sulfonamide compound for antagonizing NOD1 | 清华大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-113234029-B | Synthesis method of 2-amino-3, 5-dihalogen pyrazine | 白银康寓信生物科技有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-113234029-A | Synthesis method of 2-amino-3, 5-dihalogen pyrazine | 白银康寓信生物科技有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-108200769-B | Fused phenoxyacetamides | 勃林格殷格翰国际有限公司 | 2021-07-27 | — | — | CN | disclosed |
| CN-108135897-B | Fused benzamides | 勃林格殷格翰国际有限公司 | 2021-07-27 | — | — | CN | disclosed |
| US-10759785-B2 | Compounds | Enterprise Therapeutics Limited (GB) | 2020-09-01 | — | — | US | disclosed |
| EP-3472154-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2020-08-12 | — | — | EP | disclosed |
| EP-3337483-B1 | NOVEL ANNELATED BENZAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2019-10-09 | — | — | EP | disclosed |
| US-20190233402-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2019-08-01 | — | — | US | disclosed |
| CN-1933838-A | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1715867-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005079802-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-6060475-A | Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof | ZENECA LIMITED (GB) | 2000-05-09 | — | — | US | disclosed |
| US-5866568-A | ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| US-4293552-A | Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-RE30563-E | Preparation of benzoylureas | ELI LILLY AND COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4160834-A | INSECTICIDES | ELI LILLY AND COMPANY (US) | 1979-07-10 | — | — | US | disclosed |
| US-4133956-A | Preparation of benzoylureas | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4083977-A | Novel insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas | ELI LILLY AND COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233402-A1 | COMPOUNDS | CFTR, NHERF1, SCNN1A | GRM5 1713/4885MEN1 1141/4885KMT2A 4232/4885 |
| US-10759785-B2 | Compounds | CFTR, NHERF1, SCNN1A | GRM5 1713/4885MEN1 1141/4885KMT2A 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.